Výsledky vyhledávání - "Sarah Boross-Harmer"

Akademický článek

Tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient

Autor: Scott C. Lien, Dalam Ly, S. Y. Cindy Yang, Ben X. Wang, Derek L. Clouthier, Michael St. Paul, Ramy Gadalla, Babak Noamani, Carlos R. Garcia-Batres, Sarah Boross-Harmer, Philippe L. Bedard, Trevor J. Pugh, Anna Spreafico, Naoto Hirano, Albiruni R. A. Razak, Pamela S. Ohashi

Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)

Abstract Immunotherapies targeting PD-1/PD-L1 are now widely used in the clinic to treat a variety of malignancies. While most of the research on T cell exhaustion and PD-1 blockade has been focused on conventional αβ T cells, the contribution of i

Externí odkaz: https://doaj.org/article/fd59752fa86742a8a6eab34aa0b37b3b

Zobrazit plný text záznamu

Akademický článek

Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors

Publikováno v: Frontiers in Oncology, Vol 12 (2022)

BackgroundADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T-cells are genetically engineered autologous T-cells that express a high-affinity melanoma-associated antigen (MAGE)-A10-specific T-cell receptor (TCR) targeting MAGE-A10-positi

Externí odkaz: https://doaj.org/article/4c808abbb2f84a2ab7ad3e5e7de8a030

Zobrazit plný text záznamu

Akademický článek

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)

Purpose To evaluate whether administration of the oral DNA hypomethylating agent CC-486 enhances the poor response rate of immunologically ‘cold’ solid tumors to immune checkpoint inhibitor durvalumab.Experimental design PD-L1/PD-1 inhibitor naï

Externí odkaz: https://doaj.org/article/76a7d4cf7bd440f7a37f47994e83aedf

Zobrazit plný text záznamu

285 Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors

Autor: Svetlana Fayngerts, David S. Hong, Francine Brophy, Ecaterina Ileana Dumbrava, Partow Kebriaei, Jean-Marc Navenot, Sarah Boross-Harmer, Amy Sauer, Matthew J. Frigault, Paula M. Fracasso, Ryan J. Sullivan, Elliot Norry, Marcus O. Butler, Jane Bai, Russell K. Pachynski

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

Background ADP-A2M10 SPEAR T-cells are genetically engineered autologous T-cells that express a high affinity MAGE-A10-specific T-cell receptor targeting MAGE-A10+tumors in the context of HLA A*02. This trial is no longer enrolling (NCT02989064). Met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::069915d86b61637722825fa04a75d438
https://doaj.org/article/3cc3704b6a2e45a5bc9da899afd13797

Zobrazit plný text záznamu

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

Publikováno v: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)

PurposeTo evaluate whether administration of the oral DNA hypomethylating agent CC-486 enhances the poor response rate of immunologically ‘cold’ solid tumors to immune checkpoint inhibitor durvalumab.Experimental designPD-L1/PD-1 inhibitor naïve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8a632c6acdfdcee73755be4d872b33a
https://pubmed.ncbi.nlm.nih.gov/32753546

Zobrazit plný text záznamu

Adoptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumour responses in patients with NY-ESO-1 expressing solid tumours

Publikováno v: Annals of Oncology. 30:v481

Background We are conducting a single site, investigator-initiated Phase Ib study with TBI-1301 where autologous T cells are genetically engineered to express a high affinity NY-ESO-1-specific T cell receptor (TCR) and adoptively transferred to HLA-A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9556809de8ca31120abfb79d01e5b6a0
https://doi.org/10.1093/annonc/mdz253.009

Zobrazit plný text záznamu

Abstract CT190: A Phase II basket study of hypomethylating agent oral cc-486 and durvalumab in advanced solid tumors (METADUR)

Autor: Kirsty Taylor, Philippe L. Bedard, Daniel D. De Carvalho, Marcus O. Butler, Sarah Boross-Harmer, Lisa Wang, Neda Stjepanovic, Aaron R. Hansen, Anna Spreafico, Cescon D, Helen Loo Yau, Trevor J. Pugh, Brendan Van As, Amit M. Oza, Albiruni R. Razak, Lillian L. Siu, Ben X. Wang, Stephanie Lheureux

Publikováno v: Cancer Research. 79:CT190-CT190

Background Aberrant DNA methylation contributes to cancer initiation and progression. In preclinical models of solid tumors, chronic low dose administration of DNA hypomethylating agents can induce T-cell mediated immune activation responses by stimu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dba0a36c9b489f5aa4846b62c30b79ee
https://doi.org/10.1158/1538-7445.am2019-ct190

Zobrazit plný text záznamu

Feasibility study of microbial ecosystem therapeutics (MET-4) to evaluate effects of fecal microbiome in patients on immunotherapy (MET4-IO)

Autor: Bryan Coburn, Aida Al-Kindy, Sarah Boross-Harmer, Aaron R. Hansen, Philippe L. Bedard, Kendra Ross, Marcus O. Butler, Wei Xu, David Hogg, Lillian L. Siu, Tira Jing Ying Tan, Helen Chow, Adrian G. Sacher, Anna Spreafico

Publikováno v: Journal of Clinical Oncology. 37:TPS2664-TPS2664

TPS2664 Background: Differences in microbiome diversity and composition in immune checkpoint inhibitor (ICI)-responders vs non-responders have been demonstrated. Transplantation of responder feces in mouse models recapitulated the ICI-responsive phen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::94f1bb6046b081d400b247ab3ba697cc
https://doi.org/10.1200/jco.2019.37.15_suppl.tps2664

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání